TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Gambogic Acid, Gefitinib
Phytochemical Name Gambogic Acid (PubChem CID: 9852185 )
Anticancer drug Name Gefitinib (PubChem CID: 123631 )
Structure of
Phytochemical
2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug
2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Reversing Drug Resistance
Hide/Show
Combination Pair ID: 888
Pair Name Gambogic Acid, Gefitinib
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Down-regulation Phosphorylation MAPK3 hsa5595
Down-regulation Phosphorylation MEK1 hsa5604
In Vitro Model NCI-H1975 Lung adenocarcinoma Homo sapiens (Human) CVCL_1511
In Vivo Model The mice were subcutaneously injected with 1×10⁷ NCI-H1975 cells suspended in 100 uL of Matrigel.
Result Gefitinib in combination with GA resulted in antitumor growth in the EGFR-T790M secondary mutation NCI-H1975 tumor model due to an enhanced apoptotic effect. This novel therapeutic strategy may be a practical approach for the treatment of patients who show gefitinib resistance.
03. Reference
No. Title Href
1 Combined therapy with EGFR TKI and gambogic acid for overcoming resistance in EGFR-T790M mutant lung cancer. Oncol Lett. 2015 Oct;10(4):2063-2066. doi: 10.3892/ol.2015.3599. Click
It has been 46840 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP